Core Points - Editas Medicine, Inc. is hosting a webinar on September 2, 2025, to announce its lead in vivo development candidate [1] - The webinar will be accessible live and archived through the company's website [2] - Editas Medicine focuses on developing transformative in vivo gene editing medicines using CRISPR technology [3] Company Overview - Editas Medicine is a pioneering gene editing company that aims to translate CRISPR/Cas12a and CRISPR/Cas9 systems into a pipeline of medicines for serious diseases [3] - The company is the exclusive licensee of Broad Institute's Cas12a patent estate and Cas9 patent estates for human medicines [3] - Editas Medicine's goal is to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases [3]